Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
第一著者: | Akter, Anika |
---|---|
その他の著者: | Alam, Marzia |
フォーマット: | 学位論文 |
言語: | English |
出版事項: |
Brac University
2022
|
主題: | |
オンライン・アクセス: | http://hdl.handle.net/10361/17039 |
類似資料
-
Biologics and Biosimilars as Treatment Options for Psoriasis
著者:: Moya, Amena Khatun
出版事項: (2023) -
Importance of biologics in rheumatoid arthritis management
著者:: Riyadh, S. M.
出版事項: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
著者:: Afroza, Halima
出版事項: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
著者:: Mehreen, Elnaj
出版事項: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
著者:: Islam, Nahidul
出版事項: (2023)